FDA Risk-Evaluation Guidance Unlikely To Help Generics
By Gregory Asciolla and Matthew Perez (June 12, 2018, 2:55 PM EDT) -- Last week, the U.S. Food and Drug Administration issued two draft guidances concerning risk evaluation mitigation strategies, or REMS, which are programs designed to track the use, and deter the potential misuse, of drug products that pose significant health risks. One guidance addressed the development of a single shared system for REMS.[1] The other addressed waivers from the SSS for REMS.[2] The FDA proffered these guidances as a means of enhancing cooperation and competition in response to complaints that brand drug manufacturers were using REMS requirements "to block timely generic entry."[3] Yet, however well-intended, their substance actually reveals the limits of FDA policy and might in preventing gamesmanship in the development of SSS for REMS....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
